{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T05:06:55Z","timestamp":1773637615415,"version":"3.50.1"},"reference-count":73,"publisher":"Bentham Science Publishers Ltd.","issue":"2","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CCHTS"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:sec>\n                    <jats:title>Aims:<\/jats:title>\n                    <jats:p>The primary objective of this study is to explore the impact of Ganfule (GFL), a traditional\nChinese medicine, on differentially expressed genes (DEGs) linked to nonalcoholic fatty liver disease\n(NAFLD). By identifying potential biomarkers, we seek to enhance GFL's clinical efficacy through targeted\npharmaceutical design.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>NAFLD a prevalent liver disorder, is often associated with obesity and metabolic syndrome.\nWhile GFL has demonstrated clinical efficacy in treating NAFLD, its precise targets and mechanisms of action\nremain elusive. Understanding these mechanisms could pave the way for more effective treatments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>GFL, a long-standing traditional Chinese medicine (TCM), has demonstrated clinical effectiveness\nin treating NAFLD. However, its precise targets and mechanism of action remain elusive. In this study,\nwe aim to explore GFL's impact on differentially expressed genes, which could potentially serve as biomarkers\nfor developing targeted therapies. This approach is intended to enhance GFL's clinical efficacy by\nidentifying key genes that respond to its treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>To induce NAFLD, 23 Sprague-Dawley rats were fed a high-fat diet. These rats were then categorized\ninto three groups: normal diet (NOR), high-fat diet model (HFD), and those treated with GFL. Highthroughput\nsequencing was employed to identify DEGs in their livers. Utilizing the STRING and DAVID\ndatabases, we analyzed potential protein interactions expressed by these genes. Furthermore, the KEGG, Reactome,\nand Wiki databases aided in determining their biological roles and signaling pathways. Key DEGs'\nmRNA expression levels and corresponding proteins were further screened and confirmed through haematoxylin-\neosin staining (HE), immunohistochemistry (IHC), Real-Time Quantitative Reverse Transcription\nPolymerase Chain Reaction (RT-qPCR), and western blotting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Significant variations in DEGs were observed across the three groups, with 19 intersecting genes\nidentified within a cluster of 90 NAFLD-related genes. GFL was found to adjust the expression of nine core\nDEGs, including Abcg1, Igfgb1, Lepr, Pdk4, Socs3, and Stat3. These genes-related proteins are tied to proteins\nsuch as FABP4, LEPR, SCD1, SOCS3, and STAT3, which are intimately connected to adipocytokine\nand adipogenesis pathways. Our study reveals that GFL modifies the expression of IGFBP1, LEPR, PDK4,\nSCD1, and SOCS3, thereby regulating the adipocytokine, JAK-STAT, leptin-insulin signaling, and adipogenesis\nmetabolic pathways, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>This study enhances understanding of GFL's efficacy and identifies potential biomarkers for\nNAFLD treatment. Optimizing GFL's efficacy and elucidating its mechanism provides a methodological reference\nfor traditional Chinese medicine exploration.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/0113862073335295241216152011","type":"journal-article","created":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T06:22:26Z","timestamp":1738909346000},"page":"207-220","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Systems Biology Approach to Unraveling Transcriptomic Mechanisms of Ganfule Capsules in Ameliorating Nonalcoholic Fatty Liver Disease"],"prefix":"10.2174","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5014-9415","authenticated-orcid":true,"given":"Yu","family":"Pan","sequence":"first","affiliation":[{"name":"Guangxi Botanical Garden of Medicinal Plants, Nanning 530023, Guangxi, P.R. China"},{"name":"National Engineering Research Center of Southwest Endangered Medicinal Resource Development, Nanning 530023, Guangxi, P. R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunkun","family":"Zhang","sequence":"additional","affiliation":[{"name":"Hunan Engineering Technology Research Center for Bioactive Substance Discovery of Chinese Medicine, HunanUniversity of Chinese Medicine, Changsha 410208, P.R. China"},{"name":"Hunan Province Sino-US International Joint ResearchCenter for Therapeutic Drugs of Senile Degenerative Diseases, Hunan University of Chinese Medicine, Changsha410208, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suren R.","family":"Sooranna","sequence":"additional","affiliation":[{"name":"Academic Department of Obstetrics and Gvnaecology, Imperial CollegeLondon, Chelsea and Westminster Hospital, 369 Fulham Road, London SW10 9NH, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaonan","family":"Yang","sequence":"additional","affiliation":[{"name":"Guangxi Botanical Garden of Medicinal Plants, Nanning 530023, Guangxi, P.R. China"},{"name":"National Engineering Research Center of Southwest Endangered Medicinal Resource Development, Nanning 530023, Guangxi, P. R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaqin","family":"Zhou","sequence":"additional","affiliation":[{"name":"Guangxi Botanical Garden of Medicinal Plants, Nanning 530023, Guangxi, P.R. China"},{"name":"Chinese Medicinal Materials Product Quality Supervision and Inspection Station,Nanning,530023, Guangxi, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu","family":"Chen","sequence":"additional","affiliation":[{"name":"Guangxi Botanical Garden of Medicinal Plants, Nanning 530023, Guangxi, P.R. China"},{"name":"National Engineering Research Center of Southwest Endangered Medicinal Resource Development, Nanning 530023, Guangxi, P. R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4643-0064","authenticated-orcid":true,"given":"Fei","family":"Xu","sequence":"additional","affiliation":[{"name":"Hunan Engineering Technology Research Center for Bioactive Substance Discovery of Chinese Medicine, HunanUniversity of Chinese Medicine, Changsha 410208, P.R. China"},{"name":"Hunan Province Sino-US International Joint ResearchCenter for Therapeutic Drugs of Senile Degenerative Diseases, Hunan University of Chinese Medicine, Changsha410208, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2126-246X","authenticated-orcid":true,"given":"Danna","family":"Huang","sequence":"additional","affiliation":[{"name":"Guangxi Botanical Garden of Medicinal Plants, Nanning 530023, Guangxi, P.R. China"},{"name":"National Engineering Research Center of Southwest Endangered Medicinal Resource Development, Nanning 530023, Guangxi, P. R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","volume":"397","author":"Powell E.E.","year":"2021","unstructured":"Powell E.E.; Wong V.W.S.; Rinella M.; Non-alcoholic fatty liver disease. Lancet  2021,397(10290),2212-2224","journal-title":"Lancet"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1016\/j.jhep.2014.12.012","volume":"62","author":"Byrne C.D.","year":"2015","unstructured":"Byrne C.D.; Targher G.; NAFLD: A multisystem disease. J Hepatol  2015,62(1)(Suppl.),S47-S64","journal-title":"J Hepatol"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.3350\/cmh.2022.0367","volume":"29","author":"Gofton C.","year":"2023","unstructured":"Gofton C.; Upendran Y.; Zheng M.H.; George J.; MAFLD: How is it different from NAFLD? Clin Mol Hepatol  2023,29(Suppl.),S17-S31","journal-title":"Clin Mol Hepatol"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","volume":"15","author":"Younossi Z.","year":"2018","unstructured":"Younossi Z.; Anstee Q.M.; Marietti M.; Hardy T.; Henry L.; Eslam M.; George J.; Bugianesi E.; Global burden of NAFLD and NASH: Trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol  2018,15(1),11-20","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","volume":"24","author":"Friedman S.L.","year":"2018","unstructured":"Friedman S.L.; Neuschwander-Tetri B.A.; Rinella M.; Sanyal A.J.; Mechanisms of NAFLD development and therapeutic strategies. Nat Med  2018,24(7),908-922","journal-title":"Nat Med"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1136\/gutjnl-2020-320622","volume":"69","author":"Targher G.","year":"2020","unstructured":"Targher G.; Byrne C.D.; Tilg H.; NAFLD and increased risk of cardiovascular disease: Clinical associations, pathophysiological mechanisms and pharmacological implications. Gut  2020,69(9),1691-1705","journal-title":"Gut"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"e61","DOI":"10.1016\/j.jhep.2023.07.031","volume":"80","author":"De A.","year":"2024","unstructured":"De A.; Bhagat N.; Mehta M.; Taneja S.; Duseja A.; Metabolic dysfunction-associated steatotic liver disease (MASLD) definition is better than MAFLD criteria for lean patients with NAFLD. J Hepatol  2024,80(2),e61-e62","journal-title":"J Hepatol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"245","DOI":"10.7861\/clinmedicine.18-3-245","volume":"18","author":"Maurice J.","year":"2018","unstructured":"Maurice J.; Manousou P.; Non-alcoholic fatty liver disease. Clin Med  2018,18(3),245-250","journal-title":"Clin Med"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"4574","DOI":"10.2174\/1381612825666190117102111","volume":"24","author":"Papatheodoridi M.","year":"2019","unstructured":"Papatheodoridi M.; Cholongitas E.; Diagnosis of non-alcoholic fatty liver disease (NAFLD): Current concepts. Curr Pharm Des  2019,24(38),4574-4586","journal-title":"Curr Pharm Des"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.jhep.2018.10.033","volume":"70","author":"Younossi Z.M.","year":"2019","unstructured":"Younossi Z.M.; Non-alcoholic fatty liver disease \u2013 A global public health perspective. J Hepatol  2019,70(3),531-544","journal-title":"J Hepatol"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1038\/s41591-023-02242-6","volume":"29","author":"Harrison S.A.","year":"2023","unstructured":"Harrison S.A.; Allen A.M.; Dubourg J.; Noureddin M.; Alkhouri N.; Challenges and opportunities in NASH drug development. Nat Med  2023,29(3),562-573","journal-title":"Nat Med"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.jhep.2021.09.024","volume":"76","author":"Yip T.C.F.","year":"2022","unstructured":"Yip T.C.F.; Lee H.W.; Chan W.K.; Wong G.L.H.; Wong V.W.S.; Asian perspective on NAFLD-associated HCC. J Hepatol  2022,76(3),726-734","journal-title":"J Hepatol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"5105","DOI":"10.3748\/wjg.v25.i34.5105","volume":"25","author":"Yang J.M.","year":"2019","unstructured":"Yang J.M.; Sun Y.; Wang M.; Zhang X.L.; Zhang S.J.; Gao Y.S.; Chen L.; Wu M.Y.; Zhou L.; Zhou Y.M.; Wang Y.; Zheng F.J.; Li Y.H.; Regulatory effect of a Chinese herbal medicine formula on non-alcoholic fatty liver disease. World J Gastroenterol  2019,25(34),5105-5119","journal-title":"World J Gastroenterol"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"105849","DOI":"10.1016\/j.phrs.2021.105849","volume":"172","author":"Chen M.","year":"2021","unstructured":"Chen M.; Xie Y.; Gong S.; Wang Y.; Yu H.; Zhou T.; Huang F.; Guo X.; Zhang H.; Huang R.; Han Z.; Xing Y.; Liu Q.; Tong G.; Zhou H.; Traditional Chinese medicine in the treatment of nonalcoholic steatohepatitis. Pharmacol Res  2021,172,105849","journal-title":"Pharmacol Res"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.apsb.2019.11.017","volume":"10","author":"Yan T.","year":"2020","unstructured":"Yan T.; Yan N.; Wang P.; Xia Y.; Hao H.; Wang G.; Gonzalez F.J.; Herbal drug discovery for the treatment of nonalcoholic fatty liver disease. Acta Pharm Sin B  2020,10(1),3-18","journal-title":"Acta Pharm Sin B"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"1072376","DOI":"10.3389\/fimmu.2022.1072376","volume":"13","author":"Bao Y.","year":"2022","unstructured":"Bao Y.; Han X.; Liu D.; Tan Z.; Deng Y.; Gut microbiota: The key to the treatment of metabolic syndrome in traditional Chinese medicine \u2013 A case study of diabetes and nonalcoholic fatty liver disease. Front Immunol  2022,13,1072376","journal-title":"Front Immunol"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"155398","DOI":"10.1016\/j.phymed.2024.155398","volume":"130","author":"Liu Q.","year":"2024","unstructured":"Liu Q.; Li X.; Pan Y.; Liu Q.; Li Y.; He C.; Zheng N.; Wang Y.; Wang H.; Wang Y.; Sheng L.; Zhang B.; Shen T.; Wu G.; Li H.; Wang X.; Zhang W.; Hu Y.; Zhao Y.; Efficacy and safety of Qushi Huayu, a traditional Chinese medicine, in patients with nonalcoholic fatty liver disease in a randomized controlled trial. Phytomedicine  2024,130,155398","journal-title":"Phytomedicine"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"e34297","DOI":"10.1016\/j.heliyon.2024.e34297","volume":"10","author":"Pan Y.","year":"2024","unstructured":"Pan Y.; Qiao L.; Zhang Y.; Sooranna S.R.; Huang D.; Ou M.; Xu F.; Chen L.; Huang D.; The molecular and network mechanisms of antilipidemic potential effects of Ganfule capsules in nonalcoholic fatty liver disease. Heliyon  2024,10(14),e34297","journal-title":"Heliyon"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"889799","DOI":"10.3389\/fphar.2022.889799","volume":"13","author":"Li K.","year":"2022","unstructured":"Li K.; Xiao K.; Zhu S.; Wang Y.; Wang W.; Chinese herbal medicine for primary liver cancer therapy: Perspectives and challenges. Front Pharmacol  2022,13,889799","journal-title":"Front Pharmacol"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"110180","DOI":"10.1016\/j.intimp.2023.110180","volume":"119","author":"Meng X.","year":"2023","unstructured":"Meng X.; Kuang H.; Wang Q.; Zhang H.; Wang D.; Kang T.; A polysaccharide from Codonopsis pilosula roots attenuates carbon tetrachloride-induced liver fibrosis via modulation of TLR4\/NF-\u03baB and TGF-\u03b21\/Smad3 signaling pathway. Int Immunopharmacol  2023,119,110180","journal-title":"Int Immunopharmacol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"155338","DOI":"10.1016\/j.phymed.2024.155338","volume":"128","author":"Li N.","year":"2024","unstructured":"Li N.; Yang C.; Xia J.; Wang W.; Xiong W.; Molecular mechanisms of Codonopsis pilosula in inhibiting hepatocellular carcinoma growth and metastasis. Phytomedicine  2024,128,155338","journal-title":"Phytomedicine"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"116519","DOI":"10.1016\/j.biopha.2024.116519","volume":"175","author":"Li B.","year":"2024","unstructured":"Li B.; Jiang X.F.; Dong Y.J.; Zhang Y.P.; He X.L.S.; Zhou C.L.; Ding Y.Y.; Wang N.; Wang Y.B.; Cheng W.Q.; Jiang N.H.; Su J.; Lv G.Y.; Chen S.H.; The effects of Atractylodes macrocephala extract BZEP self-microemulsion based on gut\u2013liver axis HDL\/LPS signaling pathway to ameliorate metabolic dysfunction-associated fatty liver disease in rats. Biomed Pharmacother  2024,175,116519","journal-title":"Biomed Pharmacother"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1142\/S0192415X11008981","volume":"39","author":"Jin C.","year":"2011","unstructured":"Jin C.; Zhang P.J.; Bao C.Q.; Gu Y.L.; Xu B.H.; Li C.W.; Li J.P.; Bo P.; Liu X.N.; Protective effects of Atractylodes macrocephala polysaccharide on liver ischemia-reperfusion injury and its possible mechanism in rats. Am J Chin Med  2011,39(3),489-502","journal-title":"Am J Chin Med"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"115457","DOI":"10.1016\/j.jep.2022.115457","volume":"296","author":"Ye H.","year":"2022","unstructured":"Ye H.; Ma S.; Qiu Z.; Huang S.; Deng G.; Li Y.; Xu S.; Yang M.; Shi H.; Wu C.; Li M.; Zhang J.; Zhang F.; Qin M.; Huang H.; Zeng Z.; Wang M.; Chen Y.; Lin H.; Gao Z.; Cai M.; Song Y.; Gong S.; Gao L.; Poria cocos polysaccharides rescue pyroptosis-driven gut vascular barrier disruption in order to alleviates non-alcoholic steatohepatitis. J Ethnopharmacol  2022,296,115457","journal-title":"J Ethnopharmacol"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"1172950","DOI":"10.3389\/fphar.2023.1172950","volume":"14","author":"He J.","year":"2023","unstructured":"He J.; Yang Y.; Zhang F.; Li Y.; Li X.; Pu X.; He X.; Zhang M.; Yang X.; Yu Q.; Qi Y.; Li X.; Yu J.; Corrigendum: Effects of Poria cocos extract on metabolic dysfunction-associated fatty liver disease via the FXR\/PPAR\u03b1-SREBPs pathway. Front Pharmacol  2023,14,1172950","journal-title":"Front Pharmacol"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"5018","DOI":"10.3390\/molecules28135018","volume":"28","author":"Dong M.","year":"2023","unstructured":"Dong M.; Li J.; Yang D.; Li M.; Wei J.; Biosynthesis and pharmacological activities of flavonoids, triterpene saponins and polysaccharides derived from Astragalus membranaceus. Molecules  2023,28(13),5018","journal-title":"Molecules"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"854674","DOI":"10.3389\/fphar.2022.854674","volume":"13","author":"Zhang J.","year":"2022","unstructured":"Zhang J.; Feng Q.; Pharmacological effects and molecular protective mechanisms of astragalus polysaccharides on nonalcoholic fatty liver disease. Front Pharmacol  2022,13,854674","journal-title":"Front Pharmacol"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1093\/jpp\/rgab126","volume":"74","author":"Ao M.","year":"2022","unstructured":"Ao M.; Li X.; Liao Y.; Zhang C.; Fan S.; Hu C.; Chen Z.; Yu L.; Curcumae Radix: A review of its botany, traditional uses, phytochemistry, pharmacology and toxicology. J Pharm Pharmacol  2022,74(6),779-792","journal-title":"J Pharm Pharmacol"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"1084435","DOI":"10.3389\/fphar.2022.1084435","volume":"13","author":"Liang M.","year":"2022","unstructured":"Liang M.; Huo M.; Guo Y.; Zhang Y.; Xiao X.; Xv J.; Fang L.; Li T.; Wang H.; Dong S.; Jiang X.; Yu W.; Aqueous extract of Artemisia capillaris improves non-alcoholic fatty liver and obesity in mice induced by high-fat diet. Front Pharmacol  2022,13,1084435","journal-title":"Front Pharmacol"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1111\/jam.15307","volume":"132","author":"Xu F.","year":"2022","unstructured":"Xu F.; Li H.; Pan Y.; Zeng Y.; Li J.; Li S.; Effects of Ganfule capsule on microbial and metabolic profiles in anti-hepatocellular carcinoma. J Appl Microbiol  2022,132(3),2280-2292","journal-title":"J Appl Microbiol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"930785","DOI":"10.3389\/fphar.2022.930785","volume":"13","author":"Ke C.","year":"2022","unstructured":"Ke C.; Gao J.; Tu J.; Wang Y.; Xiao Y.; Wu Y.; Liu Y.; Zhou Z.; Ganfule capsule alleviates bile duct ligation-induced liver fibrosis in mice by inhibiting glutamine metabolism. Front Pharmacol  2022,13,930785","journal-title":"Front Pharmacol"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"479","DOI":"10.19852\/j.cnki.jtcm.20220408.003","volume":"42","author":"Jiashuo W.U.","year":"2022","unstructured":"Jiashuo W.U.; Fangqing Z.; Zhuangzhuang L.I.; Weiyi J.; Yue S.; Integration strategy of network pharmacology in Traditional Chinese Medicine: A narrative review. J Tradit Chin Med  2022,42(3),479-486","journal-title":"J Tradit Chin Med"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"116306","DOI":"10.1016\/j.jep.2023.116306","volume":"309","author":"Zhao L.","year":"2023","unstructured":"Zhao L.; Zhang H.; Li N.; Chen J.; Xu H.; Wang Y.; Liang Q.; Network pharmacology, a promising approach to reveal the pharmacology mechanism of Chinese medicine formula. J Ethnopharmacol  2023,309,116306","journal-title":"J Ethnopharmacol"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/S1875-5364(13)60037-0","volume":"11","author":"Li S.","year":"2013","unstructured":"Li S.; Zhang B.; Traditional Chinese medicine network pharmacology: Theory, methodology and application. Chin J Nat Med  2013,11(2),110-120","journal-title":"Chin J Nat Med"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"e246","DOI":"10.1016\/S1473-3099(20)30784-2","volume":"21","author":"Hoenigl M.","year":"2021","unstructured":"Hoenigl M.; Salmanton-Garc\u00eda J.; Walsh T.J.; Nucci M.; Neoh C.F.; Jenks J.D.; Lackner M.; Sprute R.; Al-Hatmi A.M.S.; Bassetti M.; Carlesse F.; Freiberger T.; Koehler P.; Lehrnbecher T.; Kumar A.; Prattes J.; Richardson M.; Revankar S.; Slavin M.A.; Stemler J.; Spiess B.; Taj-Aldeen S.J.; Warris A.; Woo P.C.Y.; Young J.A.H.; Albus K.; Arenz D.; Arsic-Arsenijevic V.; Bouchara J.P.; Chinniah T.R.; Chowdhary A.; de Hoog G.S.; Dimopoulos G.; Duarte R.F.; Hamal P.; Meis J.F.; Mfinanga S.; Queiroz-Telles F.; Patterson T.F.; Rahav G.; Rogers T.R.; Rotstein C.; Wahyuningsih R.; Seidel D.; Cornely O.A.; Global guideline for the diagnosis and management of rare mould infections: An initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology and the American Society for Microbiology. Lancet Infect Dis  2021,21(8),e246-e257","journal-title":"Lancet Infect Dis"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1021\/acs.analchem.3c05213","volume":"96","author":"Vanness B.C.","year":"2024","unstructured":"Vanness B.C.; Linz T.H.; Multiplexed miRNA and protein analysis using digital quantitative pcr in microwell arrays. Anal Chem  2024,96(3),1371-1379","journal-title":"Anal Chem"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"8360","DOI":"10.1038\/s41598-022-12201-9","volume":"12","author":"Jha K.","year":"2022","unstructured":"Jha K.; Saha S.; Singh H.; Prediction of protein\u2013protein interaction using graph neural networks. Sci Rep  2022,12(1),8360","journal-title":"Sci Rep"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"794","DOI":"10.3390\/ijms23020794","volume":"23","author":"Xie R.","year":"2022","unstructured":"Xie R.; Li B.; Jia L.; Li Y.; Identification of core genes and pathways in melanoma metastasis via bioinformatics analysis. Int J Mol Sci  2022,23(2),794","journal-title":"Int J Mol Sci"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"100070","DOI":"10.1016\/j.labinv.2023.100070","volume":"103","author":"Koivukoski S.","year":"2023","unstructured":"Koivukoski S.; Khan U.; Ruusuvuori P.; Latonen L.; Unstained tissue imaging and virtual hematoxylin and eosin staining of histologic whole slide images. Lab Invest  2023,103(5),100070","journal-title":"Lab Invest"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"537","DOI":"10.5858\/2010-0702-RAIR.1","volume":"135","author":"Engel K.B.","year":"2011","unstructured":"Engel K.B.; Moore H.M.; Effects of preanalytical variables on the detection of proteins by immunohistochemistry in formalin-fixed, paraffin-embedded tissue. Arch Pathol Lab Med  2011,135(5),537-543","journal-title":"Arch Pathol Lab Med"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1038\/nprot.2006.236","volume":"1","author":"Nolan T.","year":"2006","unstructured":"Nolan T.; Hands R.E.; Bustin S.A.; Quantification of mRNA using real-time RT-PCR. Nat Protoc  2006,1(3),1559-1582","journal-title":"Nat Protoc"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1373\/clinchem.2010.149765","volume":"57","author":"Burnette W.N.","year":"2011","unstructured":"Burnette W.N.; Western Blotting. Clin Chem  2011,57(1),132-133","journal-title":"Clin Chem"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"21","DOI":"10.7334\/psicothema2022.292","volume":"35","author":"Blanca M.J.","year":"2023","unstructured":"Blanca M.J.; Arnau J.; Garc\u00eda-Castro F.J.; Alarc\u00f3n R.; Bono R.; Non-normal data in repeated measures ANOVA: Impact on type i error and power. Psicothema  2023,35(1),21-29","journal-title":"Psicothema"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1186\/s12885-020-06722-7","volume":"20","author":"Xu J.","year":"2020","unstructured":"Xu J.; Liao K.; Fu Z.; Xiong Z.; Screening differentially expressed genes of pancreatic cancer between Mongolian and Han people using bioinformatics technology. BMC Cancer  2020,20(1),298","journal-title":"BMC Cancer"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1002\/ncp.10449","volume":"35","author":"Mundi M.S.","year":"2020","unstructured":"Mundi M.S.; Velapati S.; Patel J.; Kellogg T.A.; Abu Dayyeh B.K.; Hurt R.T.; Evolution of NAFLD and its management. Nutr Clin Pract  2020,35(1),72-84","journal-title":"Nutr Clin Pract"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"e43028","DOI":"10.1371\/journal.pone.0043028","volume":"7","author":"Rocha-Martins M.","year":"2012","unstructured":"Rocha-Martins M.; Njaine B.; Silveira M.S.; Avoiding pitfalls of internal controls: Validation of reference genes for analysis by qRT-PCR and Western blot throughout rat retinal development. PLoS One  2012,7(8),e43028","journal-title":"PLoS One"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s12902-022-00980-1","volume":"22","author":"Pouwels S.","year":"2022","unstructured":"Pouwels S.; Sakran N.; Graham Y.; Leal A.; Pintar T.; Yang W.; Kassir R.; Singhal R.; Mahawar K.; Ramnarain D.; Non-alcoholic fatty liver disease (NAFLD): A review of pathophysiology, clinical management and effects of weight loss. BMC Endocr Disord  2022,22(1),63","journal-title":"BMC Endocr Disord"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1038\/s42255-021-00501-9","volume":"3","author":"Tilg H.","year":"2021","unstructured":"Tilg H.; Adolph T.E.; Dudek M.; Knolle P.; Non-alcoholic fatty liver disease: The interplay between metabolism, microbes and immunity. Nat Metab  2021,3(12),1596-1607","journal-title":"Nat Metab"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1080\/00365521.2017.1379556","volume":"52","author":"Hagstr\u00f6m H.","year":"2017","unstructured":"Hagstr\u00f6m H.; St\u00e5l P.; Hultcrantz R.; Brismar K.; Ansurudeen I.; IGFBP-1 and IGF-I as markers for advanced fibrosis in NAFLD \u2013 A pilot study. Scand J Gastroenterol  2017,52(12),1427-1434","journal-title":"Scand J Gastroenterol"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"217","DOI":"10.3390\/biom11020217","volume":"11","author":"Bailes J.","year":"2021","unstructured":"Bailes J.; Soloviev M.; Insulin-like growth factor-1 (IGF-1) and its monitoring in medical diagnostic and in sports. Biomolecules  2021,11(2),217","journal-title":"Biomolecules"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"e520","DOI":"10.1210\/clinem\/dgaa792","volume":"106","author":"Stanley T.L.","year":"2021","unstructured":"Stanley T.L.; Fourman L.T.; Zheng I.; McClure C.M.; Feldpausch M.N.; Torriani M.; Corey K.E.; Chung R.T.; Lee H.; Kleiner D.E.; Hadigan C.M.; Grinspoon S.K.; Relationship of IGF-1 and IGF-binding proteins to disease severity and glycemia in nonalcoholic fatty liver disease. J Clin Endocrinol Metab  2021,106(2),e520-e533","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.cellbi.2003.12.003","volume":"28","author":"Hegyi K.","year":"2004","unstructured":"Hegyi K.; F\u00fcl\u00f6p K.; Kov\u00e1cs K.; T\u00f3th S.; Falus A.; Leptin\u2010induced signal transduction pathways. Cell Biol Int  2004,28(3),159-169","journal-title":"Cell Biol Int"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/S0739-7240(98)00035-6","volume":"15","author":"Houseknecht K.L.","year":"1998","unstructured":"Houseknecht K.L.; Portocarrero C.P.; Leptin and its receptors: Regulators of whole-body energy homeostasis. Domest Anim Endocrinol  1998,15(6),457-475","journal-title":"Domest Anim Endocrinol"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"154028","DOI":"10.1016\/j.metabol.2019.154028","volume":"103","author":"Boutari C.","year":"2020","unstructured":"Boutari C.; Mantzoros C.S.; Adiponectin and leptin in the diagnosis and therapy of NAFLD. Metabolism  2020,103,154028","journal-title":"Metabolism"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"274","DOI":"10.4093\/kdj.2010.34.5.274","volume":"34","author":"Jeoung N.H.","year":"2010","unstructured":"Jeoung N.H.; Harris R.A.; Role of pyruvate dehydrogenase kinase 4 in regulation of blood glucose levels. Korean Diabetes J  2010,34(5),274-283","journal-title":"Korean Diabetes J"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.mito.2019.07.009","volume":"49","author":"Pettersen I.K.N.","year":"2019","unstructured":"Pettersen I.K.N.; Tusubira D.; Ashrafi H.; Dyrstad S.E.; Hansen L.; Liu X.Z.; Nilsson L.I.H.; L\u00f8vsletten N.G.; Berge K.; Wergedahl H.; Bj\u00f8rndal B.; Fluge \u00d8.; Bruland O.; Rustan A.C.; Halberg N.; R\u00f8sland G.V.; Berge R.K.; Tronstad K.J.; Upregulated PDK4 expression is a sensitive marker of increased fatty acid oxidation. Mitochondrion  2019,49,97-110","journal-title":"Mitochondrion"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1242\/jcs.167049","volume":"128","author":"Hou X.","year":"2015","unstructured":"Hou X.; Zhang L.; Han L.; Ge J.; Ma R.; Zhang X.; Moley K.; Schedl T.; Wang Q.; Differing roles of pyruvate dehydrogenase kinases during mouse oocyte maturation. J Cell Sci  2015,128(13),2319-2329","journal-title":"J Cell Sci"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.freeradbiomed.2019.06.019","volume":"141","author":"Zhu X.","year":"2019","unstructured":"Zhu X.; Bian H.; Wang L.; Sun X.; Xu X.; Yan H.; Xia M.; Chang X.; Lu Y.; Li Y.; Xia P.; Li X.; Gao X.; Berberine attenuates nonalcoholic hepatic steatosis through the AMPK-SREBP-1c-SCD1 pathway. Free Radic Biol Med  2019,141,192-204","journal-title":"Free Radic Biol Med"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.bbrc.2017.11.054","volume":"495","author":"Zhang M.","year":"2018","unstructured":"Zhang M.; Zhao Y.; Li Z.; Wang C.; Pyruvate dehydrogenase kinase 4 mediates lipogenesis and contributes to the pathogenesis of nonalcoholic steatohepatitis. Biochem Biophys Res Commun  2018,495(1),582-586","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1071\/RD12272","volume":"25","author":"Wathes D.C.","year":"2013","unstructured":"Wathes D.C.; Clempson A.M.; Pollott G.E.; Associations between lipid metabolism and fertility in the dairy cow. Reprod Fertil Dev  2013,25(1),48-61","journal-title":"Reprod Fertil Dev"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.plipres.2013.12.001","volume":"53","author":"Nakamura M.T.","year":"2014","unstructured":"Nakamura M.T.; Yudell B.E.; Loor J.J.; Regulation of energy metabolism by long-chain fatty acids. Prog Lipid Res  2014,53,124-144","journal-title":"Prog Lipid Res"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"100346","DOI":"10.1016\/j.jhepr.2021.100346","volume":"3","author":"Parlati L.","year":"2021","unstructured":"Parlati L.; R\u00e9gnier M.; Guillou H.; Postic C.; New targets for NAFLD. JHEP Reports  2021,3(6),100346","journal-title":"JHEP Reports"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1016\/j.cmet.2021.06.012","volume":"33","author":"Clifford B.L.","year":"2021","unstructured":"Clifford B.L.; Sedgeman L.R.; Williams K.J.; Morand P.; Cheng A.; Jarrett K.E.; Chan A.P.; Brearley-Sholto M.C.; Wahlstr\u00f6m A.; Ashby J.W.; Barshop W.; Wohlschlegel J.; Calkin A.C.; Liu Y.; Thorell A.; Meikle P.J.; Drew B.G.; Mack J.J.; Marschall H.U.; Tarling E.J.; Edwards P.A.; de Aguiar Vallim T.Q.; FXR activation protects against NAFLD via bile-acid-dependent reductions in lipid absorption. Cell Metab  2021,33(8),1671-1684.e4","journal-title":"Cell Metab"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"15338","DOI":"10.1096\/fj.202000836RR","volume":"34","author":"Zhang N.","year":"2020","unstructured":"Zhang N.; Wang Y.; Zhang J.; Liu B.; Deng X.; Xin S.; Xu K.; N\u2010glycosylation of CREBH improves lipid metabolism and attenuates lipotoxicity in NAFLD by modulating PPAR\u03b1 and SCD\u20101. FASEB J  2020,34(11),15338-15363","journal-title":"FASEB J"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.apsb.2021.09.019","volume":"12","author":"Du D.","year":"2022","unstructured":"Du D.; Liu C.; Qin M.; Zhang X.; Xi T.; Yuan S.; Hao H.; Xiong J.; Metabolic dysregulation and emerging therapeutical targets for hepatocellular carcinoma. Acta Pharm Sin B  2022,12(2),558-580","journal-title":"Acta Pharm Sin B"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"154733","DOI":"10.1016\/j.cyto.2019.154733","volume":"121","author":"Khan M.G.M.","year":"2019","unstructured":"Khan M.G.M.; Ghosh A.; Variya B.; Santharam M.A.; Kandhi R.; Ramanathan S.; Ilangumaran S.; Hepatocyte growth control by SOCS1 and SOCS3. Cytokine  2019,121,154733","journal-title":"Cytokine"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"492","DOI":"10.3390\/nu9050492","volume":"9","author":"Amato A.","year":"2017","unstructured":"Amato A.; Caldara G.F.; Nuzzo D.; Baldassano S.; Picone P.; Rizzo M.; Mul\u00e8 F.; Di Carlo M.; NAFLD and atherosclerosis are prevented by a natural dietary supplement containing curcumin, silymarin, guggul, chlorogenic acid and inulin in mice fed a high-fat diet. Nutrients  2017,9(5),492","journal-title":"Nutrients"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"58","DOI":"10.3389\/fimmu.2014.00058","volume":"5","author":"Carow B.","year":"2014","unstructured":"Carow B.; Rottenberg M.E.; SOCS3, a major regulator of infection and inflammation. Front Immunol  2014,5,58","journal-title":"Front Immunol"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.ghir.2005.07.001","volume":"15","author":"Dominici F.P.","year":"2005","unstructured":"Dominici F.P.; Argentino D.P.; Mu\u00f1oz M.C.; Miquet J.G.; Sotelo A.I.; Turyn D.; Influence of the crosstalk between growth hormone and insulin signalling on the modulation of insulin sensitivity. Growth Horm IGF Res  2005,15(5),324-336","journal-title":"Growth Horm IGF Res"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"3002","DOI":"10.1111\/febs.13709","volume":"283","author":"Gurzov E.N.","year":"2016","unstructured":"Gurzov E.N.; Stanley W.J.; Pappas E.G.; Thomas H.E.; Gough D.J.; The JAK\/STAT pathway in obesity and diabetes. FEBS J  2016,283(16),3002-3015","journal-title":"FEBS J"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.jcmgh.2021.08.019","volume":"13","author":"Wang F.","year":"2022","unstructured":"Wang F.; Zhang X.; Liu W.; Zhou Y.; Wei W.; Liu D.; Wong C.C.; Sung J.J.Y.; Yu J.; Activated natural killer cell promotes nonalcoholic steatohepatitis through mediating JAK\/STAT pathway. Cell Mol Gastroenterol Hepatol  2022,13(1),257-274","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s13020-021-00469-4","volume":"16","author":"Dai X.","year":"2021","unstructured":"Dai X.; Feng J.; Chen Y.; Huang S.; Shi X.; Liu X.; Sun Y.; Traditional Chinese Medicine in nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives. Chin Med  2021,16(1),68","journal-title":"Chin Med"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"1356225","DOI":"10.3389\/fmed.2024.1356225","volume":"11","author":"Wang N.","year":"2024","unstructured":"Wang N.; Que H.; Luo Q.; Zheng W.; Li H.; Wang Q.; Gu J.; Mechanisms of ferroptosis in nonalcoholic fatty liver disease and therapeutic effects of traditional Chinese medicine: A review. Front Med  2024,11,1356225","journal-title":"Front Med"}],"container-title":["Combinatorial Chemistry &amp; High Throughput Screening"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113862073335295241216152011","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/239133\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113862073335295241216152011","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T04:10:00Z","timestamp":1773634200000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/239133\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":73,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0113862073335295241216152011","relation":{},"ISSN":["1386-2073"],"issn-type":[{"value":"1386-2073","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Double blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2024-07-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-16","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}